Lonza and Index Ventures, a venture capital investment firm, have entered an exclusive agreement for process development and cGMP production of all biologics for Index Ventures’ portfolio of companies. The companies may add projects during the five-year agreement, as Index makes future investments.   “This agreement shows that Lonza’s value to a company’s product development pipeline is being recognized more widely by investors in biotech companies,” said Dr. Stephan Kutzer, chief operating offi...